Dijon, France, June 16, 2010 - Oncodesign Biotechnology(R) announced today that it has signed a licensing agreement with Janssen Pharmaceutica NV (hereinafter Janssen) related to Janssen’s macrocyclic chemistry technology. Oncodesign will have exclusive access to this technology for six years.
The technology will be one of the cornerstones of Oncodesign's integrated drug discovery efforts, together with the in vitro and in vivo translational research capabilities in oncology already established at the company. Terms of the agreement were not disclosed but grant Oncodesign a license to use and develop the technology in its internal and partnered research programs.
"This technology is a perfect complement to our well recognized expertise and capabilities in oncology, and most notably to our translational in vivo and ex vivo pharmacology models based on low passage xenografts directly derived from patient tumour material, and allows us to present a unique translational discovery platform to our clients," said Philippe Genne, President and CEO of Oncodesign.
"Having access to highly potent and selective kinase inhibitors has the potential to transform the use of this therapeutic approach in oncology as well as other therapeutic areas," added Jan Hoflack, CSO of Oncodesign.
Oncodesign Biotechnology(R)’s prime goal since its conception has been the identification of novel anticancer therapies. The company has developed an innovative preclinical research platform that allows establishing in vitro and in vivo proof of concept of potential therapeutic agents. Its pharmacology based “Drug Positioning Platform”, aiming at the rapid evaluation of the therapeutic potential of new molecules and the translational perspective of Oncodesign create a continuum from drug target to patient.
In addition to its service offering, Oncodesign has significantly invested in its own technological R&D programs to increase its innovation base. Recently, Oncodesign has taken the lead in two important national initiatives, CReMEC (Medicen, Paris), which aims at the creation of a French resource centre for experimental oncology models based on primary tumour material, and Pharmimage(R), a centre of excellence in pharmaco-imaging (Dijon, France).
Starting from these research platforms, Oncodesign has continued to develop its business scope over the last year and is now offering capability and experience to discover novel therapeutic and diagnostic agents through an integrated stand-alone approach.
Founded in 1995 by Dr Philippe Genne, Oncodesign Biotechnology (R) is based in Dijon, France. It employs 55 people including 12 PhDs and has a client-base of over 400 large and small companies.
For more information on Oncodesign Biotechnology’s R&D platform and its services:http://www.oncodesign.com/ .